All In Biotech

NDA 213150 · Tolmar

Fensolvi Kit

Leuprolide Acetate · Subcutaneous

Novel

Last checked: Nov 20, 2026Latest source record: Sep 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

May 1, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

457

123 Phase 3, 53 recruiting

FAERS reports

7,739

6,129 serious, 1,131 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 25, 2025.

FENSOLVI ® is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP). FENSOLVI is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty.

Mechanism: Leuprolide acetate, a GnRH agonist, acts as a potent inhibitor of gonadotropin secretion (LH and follicle stimulating hormone (FSH)) when given continuously in therapeutic doses. Following an initial stimulation of GnRH receptors, chronic administration of leuprolide acetate results in downregulation of GnRH receptors, reduction in release of LH, FSH and consequent suppression of ovarian and testicular production of estradiol and testosterone respectively. This inhibitory effect is reversible upon discontinuation of drug therapy.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 1, 2020 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated NovelLabelLetterReview
1 products under this application
  • FENSOLVI KIT · LEUPROLIDE ACETATE 45MG · POWDER, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Leuprolide" as an intervention, any sponsor and status, largest first.

All 457 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use529
  • drug ineffective448
  • fatigue393
  • hot flush292
  • fall282
  • asthenia276
  • death268
  • pneumonia249
  • prostate cancer236
  • nausea228
  • anaemia222
  • intercepted product preparation error213

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200483
200596
200685
2007119
2008351
2009153
2010237
2011236
2012301
201360
201456
2015138
2016113
2017126
2018152
2019160
2020207
2021530
2022930
2023953
2024863
2025973
2026817

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 567 on PubMed

Sponsor: Tolmar

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.